Eyad Almasri, MD
Pulmonary Disease · Fresno, CANPI 1992840490
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Sanofi at 41.1% of the total. That places this record below the midpoint for pulmonary disease clinicians in CA, where the typical reported total is $1,248.
Across 8 payments — averaging $75.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$247
- Insmed, Inc.$143
- Pfizer$127
- Merck$54
- AstraZeneca$29
Across 27 payments — averaging $9332.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotest AG$127K
- United Therapeutics Corporation$49K
- Merck$39K
- Bayer$20K
- Janssen Research & Development, LLC$17K
What the payments were for
- Food & beverage$54691%
- Education$549%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 2 | $247 |
| Insmed, Inc. | 1 | $143 |
| Pfizer | 1 | $127 |
| Merck | 3 | $54 |
| AstraZeneca | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELREXFIO$127
How this compares
$600 in reported general payments places this provider in the 40th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $43,596 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $15,973 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $3,093 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,736 |
| Fluticasone Propionate | 12 | $369 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $302 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Fresno
- Vijay BalasubramanianFresno$529K
- Vijai DanielFresno$471K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.